Log In
Print
BCIQ
Print
Print this Print this
 

Incruse Ellipta, Umeclidinium bromide

Also known as: Incruse

  Manage Alerts
Collapse Summary General Information
Company GlaxoSmithKline plc
DescriptionLong-acting muscarinic antagonist (LAMA) delivered via the Ellipta inhaler
Molecular Target Muscarinic receptor
Mechanism of ActionMuscarinic receptor antagonist
Therapeutic ModalityMedical Devices: Drug/device combination
Latest Stage of DevelopmentApproved
Standard IndicationChronic obstructive pulmonary disease (COPD)
Indication DetailsTreat chronic obstructive pulmonary disease (COPD)
Regulatory Designation

U.S. - Undisclosed Review (Treat chronic obstructive pulmonary disease (COPD));
EU - Standard Review (Treat chronic obstructive pulmonary disease (COPD));
Japan - Standard Review (Treat chronic obstructive pulmonary disease (COPD))

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today